Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
about
Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancersPersonalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.Expected population impacts of discontinued prostate-specific antigen screening.What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaThe prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.The impact of PLCO control arm contamination on perceived PSA screening efficacy.Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer ScreeningEffects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial.Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesEvaluation of new technologies for cancer control based on population trends in disease incidence and mortality.Individualized estimates of overdiagnosis in screen-detected prostate cancer.Risk stratification in prostate cancer screening.Is prostate cancer different in black men? Answers from 3 natural history models.Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
P2860
Q28387198-2945D2D4-BA59-467D-9630-7536EA4F521FQ34159375-6B59C300-00DC-413F-8516-11AF37F3BF4FQ34326169-2D836CC1-99E5-4689-ABBC-56D6483A3E05Q34458237-3DF6E2A0-03DC-42E7-9E5B-A048D465347FQ34963971-11455FDA-DC77-4C46-88DD-534C3B704A37Q35251546-C2C5BB9C-7AC9-4E97-9C83-0F2DFF0B3C37Q35541638-A36BA84B-0E62-4E6A-A208-63F4D21FBBCAQ36179431-C7CF6ECF-5A03-4FE4-9207-E218BA72DB95Q36567476-4A03397F-50D2-4486-8C91-4518FA82EF30Q36706929-ADCD10A5-AD59-41B7-B5DB-F963121BADADQ36953558-FB71D3A8-8EE0-4867-8CDE-6BD6F0D1D223Q37095655-8D973316-DCE1-4348-952F-E5AC0CDE0F03Q37106776-B17F95C5-E111-4F3E-A8AD-CBB9CC7EF1C3Q37634486-020DFE97-BFEB-46F4-B51B-AE7AA420F65AQ38068114-D3147A85-CED0-4A8B-9CBD-77A07A9F0BA5Q38823794-740DC940-6C5D-416F-A024-EBCB1724F975Q39289771-07135491-0956-4ECC-B2C3-5CC736686424Q44871406-04371120-DC1C-47A9-B835-355ED18CDBDBQ47358352-0A3CF76B-EBD0-4E9C-98F3-B13816573359Q48165110-0A89E8AB-E7A8-4A24-B10E-4708E12D141B
P2860
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Calibrating disease progressio ...... development in cancer control
@ast
Calibrating disease progressio ...... development in cancer control
@en
type
label
Calibrating disease progressio ...... development in cancer control
@ast
Calibrating disease progressio ...... development in cancer control
@en
prefLabel
Calibrating disease progressio ...... development in cancer control
@ast
Calibrating disease progressio ...... development in cancer control
@en
P2093
P2860
P356
P1433
P1476
Calibrating disease progressio ...... development in cancer control
@en
P2093
Jeffrey Katcher
Lurdes Inoue
Roman Gulati
Ruth Etzioni
William Hazelton
P2860
P304
P356
10.1093/BIOSTATISTICS/KXQ036
P577
2010-06-07T00:00:00Z